Biopharmaceutics & Drug disPosition

Papers
(The TQCC of Biopharmaceutics & Drug disPosition is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
20
In situ evaluation of the impact of metformin or verapamil coadministration with vildagliptin on its regional absorption from the rabbit’s intestine17
17
Decreased plasma acetaminophen glucuronide/acetaminophen concentration ratio warns the onset of acetaminophen‐induced liver injury16
Aging and brain free cholesterol concentration on amyloid‐β peptide accumulation in guinea pigs14
Absorption, metabolism, and pharmacokinetic profile of xanthohumol in rats as determined via UPLC‐MS/MS13
Evaluation of bottom‐up modeling of the blood–brain barrier to improve brain penetration prediction via physiologically based pharmacokinetic modeling12
Issue Information11
Evaluating gender effect in the generic bioequivalence studies by physiologically based pharmacokinetic modeling – A case study of dextromethorphan modified release tablets9
Evaluation of sex differences in the pharmacokinetics of oral sumatriptan in healthy Korean subjects using population pharmacokinetic modeling8
8
Self‐micellizing solid dispersion of tacrolimus: Physicochemical and pharmacokinetic characterization8
Issue Information7
Issue Information7
Issue Information7
Evidence for cytochrome P450 3A4‐mediated metabolic activation of SCO‐2677
Issue Information7
Norvancomycin plasma concentration monitoring in hemodialysis patients with end stage kidney disease: A retrospective cohort study6
Estimation of fraction of drug metabolism by a single UDP‐glucuronosyl transferase enzyme using relative expression factor6
Novel Enteric Microsphere of Beclomethasone Dipropionate With Colon Delivery and Enhancement of Anti‐Inflammatory Effects6
Utility of cystatin C and serum creatinine‐based glomerular filtration rate equations in predicting vancomycin clearance: A population pharmacokinetics analysis in elderly Chinese patients6
Metabolism and pharmacokinetic study of deuterated osimertinib6
Attenuation of phenobarbital‐induced cytochrome P450 expression in carbon tetrachloride‐induced hepatitis in mice models6
Physiologically based pharmacokinetic modelling of acetaminophen in preterm neonates—The impact of metabolising enzyme ontogeny and reduced cardiac output5
Irinotecan‐induced gastrointestinal damage alters the expression of peptide transporter 1 and absorption of cephalexin in rats5
Inhibition of canalicular and sinusoidal taurocholate efflux by cholestatic drugs in human hepatoma HepaRG cells5
Pharmacokinetic control of orally dosed cyclosporine A with mucosal drug delivery system5
Metabolism, pharmacokinetics, and anticonvulsant activity of a deuterated analog of the α2/3‐selective GABAkine KRM‐II‐815
Involvement of SLC16A1/MCT1 and SLC16A3/MCT4 in l‐lactate transport in the hepatocellular carcinoma cell line4
Predicting transporter mediated drug–drug interactions via static and dynamic physiologically based pharmacokinetic modeling: A comprehensive insight on where we are now and the way forward4
Species Differences in Carboxylesterases Among Humans, Cynomolgus Monkeys, and Mice in the Hydrolysis of Atorvastatin Derivatives4
Physiologically‐based pharmacokinetic model for alectinib, ruxolitinib, and panobinostat in the presence of cancer, renal impairment, and hepatic impairment4
4
Integration of artificial neural network and physiologically based biopharmaceutic models in the development of sustained‐release formulations4
Intestinal absorption pathways of lisinopril: Mechanistic investigations4
3
Issue Information3
Identification and characterization of an endogenous biomarker of the renal vectorial transport (OCT2‐MATE1)3
Metabolism of testosterone and progesterone by cytochrome P450 2C19 allelic variants3
Prediction of basic drug exposure in milk using a lactation model algorithm integrated within a physiologically based pharmacokinetic model3
Issue Information3
3
In vitro and ex vivo experimental models for evaluation of intranasal systemic drug delivery as well as direct nose‐to‐brain drug delivery3
Shared learning from a physiologically based pharmacokinetic modeling strategy for human pharmacokinetics prediction through retrospective analysis of Genentech compounds3
3
Icaritin exhibits potential drug–drug interactions through the inhibition of human UDP‐glucuronosyltransferase in vitro3
3
0.099087953567505